Ublituximab
UTX-TGR-205
Phase 3 mab terminated
Quick answer
Ublituximab for Diffuse Large B-Cell Lymphoma is a Phase 3 program (mab) at TG THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TG THERAPEUTICS, INC.
- Indication
- Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Modality
- mab
- Status
- terminated